MicroRNA-155 controls Toll-like receptor 3- and hepatitis C virus-induced immune responses in the liver

Journal of Viral Hepatitis

Volumn 21, Issue 2, 2014, Pages 99-110

  Jiang, M ^a,b   Broering, R ^a   Trippler, M ^a   Wu, J ^b   Zhang, E ^a,b   Zhang, X ^a,b   Gerken, G ^a   Lu, M ^a,b   Schlaak, J F ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

hepatitis C virus; interleukin 10; Kupffer cells; liver sinusoidal endothelial cells; miR 155; transforming growth factor beta

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 10; MICRORNA 155; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; MICRORNA; MIRN155 MICRORNA, HUMAN; MIRN155 MICRORNA, MOUSE; TLR3 PROTEIN, HUMAN; TLR3 PROTEIN, MOUSE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME INHIBITION; GENE EXPRESSION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION RESISTANCE; INNATE IMMUNITY; KUPFFER CELL; LIVER; LIVER BIOPSY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; GENE EXPRESSION PROFILING; HEPACIVIRUS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; KUPFFER CELLS; LIVER; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICRORNAS; TOLL-LIKE RECEPTOR 3;

EID: 84891828421     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12126     Document Type: Article

References (49)

1. Guidotti LG, Chisari FV,. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006; 1: 23-61.
2. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364 (25): 2405-2416.
3. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364 (13): 1195-1206.
4. Sumpter R Jr, Loo YM, Foy E, et al,. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol 2005; 79 (5): 2689-2699.
5. Seki E, Brenner DA,. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008; 48 (1): 322-335.
6. Broering R, Lu M, Schlaak JF,. Toll like receptors in chronic viral hepatitis-friend and foe. In:, Sergey LM, ed. Viral Hepatitis-Selected Issues of Pathogenesis and Diagnostics, Manhattan: InTech, 2011: 41-64.
7. Li K, Foy E, Ferreon JC, et al,. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102 (8): 2992-2997.
8. Foy E, Li K, Sumpter R Jr, et al,. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102 (8): 2986-2991.
9. Knolle PA, Gerken G,. Local control of the immune response in the liver. Immunol Rev 2000; 174: 21-34.
10. Crispe IN,. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163.
11. Broering R, Wu J, Meng Z, et al,. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol 2008; 48 (6): 914-922.
12. Wu J, Lu M, Meng Z, et al,. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 2007; 46 (6): 1769-1778.
13. Wang B, Trippler M, Pei R, et al,. Toll-like receptor activated human and murine hepatic stellate cells are potent regulators of hepatitis C virus replication. J Hepatol 2009; 51 (6): 1037-1045.
14. Miyazaki M, Kanto T, Inoue M, et al,. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J Med Virol 2008; 80 (6): 980-988.
15. Ding SW, Lu R,. Virus-derived siRNAs and piRNAs in immunity and pathogenesis. Curr Opin Virol 2011; 1 (6): 533-544.
16. Boldin MP, Baltimore D,. MicroRNAs, new effectors and regulators of NF-kappaB. Immunol Rev 2012; 246 (1): 205-220.
17. Ma X, Becker Buscaglia LE, Barker JR, Li Y,. MicroRNAs in NF-kappaB signaling. J Mol Cell Biol 2011; 3 (3): 159-166.
18. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D,. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A 2007; 104 (5): 1604-1609.
19. Bala S, Tilahun Y, Taha O, et al,. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 2012; 10 (1): 151.
20. Wu J, Meng Z, Jiang M, et al,. HBV suppresses toll-like receptor mediated innate immune responses in murine parenchymal and non-parenchymal liver cells. Hepatology 2009; 49 (4): 1132-1140.
21. Wu J, Meng Z, Jiang M, et al,. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010; 129 (3): 363-374.
22. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr,. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454 (7203): 523-527.
23. Nelson DR, Lauwers GY, Lau JY, Davis GL,. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118 (4): 655-660.
24. Knodler A, Schmidt SM, Bringmann A, et al,. Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells. Leukemia 2009; 23 (3): 535-544.
25. Hennig BJ, Frodsham AJ, Hellier S, et al,. Influence of IL-10RA and IL-22 polymorphisms on outcome of hepatitis C virus infection. Liver Int 2007; 27 (8): 1134-1143.
26. Nelson DR, Tu Z, Soldevila-Pico C, et al,. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38 (4): 859-868.
27. Flynn JK, Dore GJ, Hellard M, et al,. Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users. J Viral Hepat 2011; 18 (8): 549-561.
28. van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ,. Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 2008; 124 (4): 445-452.
29. Zhao J, Yang X, Auh SL, Kim KD, Tang H, Fu YX,. Do adaptive immune cells suppress or activate innate immunity? Trends Immunol 2009; 30 (1): 8-12.
30. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y,. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006; 176 (3): 1582-1587.
31. Maloy KJ, Salaun L, Cahill R, Dougan G, Saunders NJ, Powrie F,. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003; 197 (1): 111-119.
32. Hall CH, Kassel R, Tacke RS, Hahn YS,. HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS ONE 2010; 5 (8): e12154.
33. Taniguchi H, Kato N, Otsuka M, et al,. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004; 72 (1): 52-59.
34. Boudreau HE, Emerson SU, Korzeniowska A, Jendrysik MA, Leto TL,. Hepatitis C virus (HCV) proteins induce NADPH oxidase 4 expression in a transforming growth factor beta-dependent manner: a new contributor to HCV-induced oxidative stress. J Virol 2009; 83 (24): 12934-12946.
35. Lin W, Tsai WL, Shao RX, et al,. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010; 138 (7): 2509-2518.
36. Alatrakchi N, Graham CS, van der Vliet HJ, Sherman KE, Exley MA, Koziel MJ,. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses. J Virol 2007; 81 (11): 5882-5892.
37. Kimura T, Saito T, Yoshimura M, et al,. Association of transforming growth factor-beta 1 functional polymorphisms with natural clearance of hepatitis C virus. J Infect Dis 2006; 193 (10): 1371-1374.
38. Lee S, Varano J, Flexman JP, et al,. Decreased IP-10 and elevated TGFbeta1 levels are associated with viral clearance following therapy in patients with hepatitis C virus. Dis Markers 2010; 28 (5): 273-280.
39. Fietta P, Delsante G,. The effector T helper cell triade. Riv Biol 2009; 102 (1): 61-74.
40. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD,. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008; 9 (8): 839-845.
41. Xiao C, Rajewsky K,. MicroRNA control in the immune system: basic principles. Cell 2009; 136 (1): 26-36.
42. Gottwein E, Cullen BR,. Viral and cellular microRNAs as determinants of viral pathogenesis and immunity. Cell Host Microbe 2008; 3 (6): 375-387.
43. Faraoni I, Antonetti FR, Cardone J, Bonmassar E,. miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta 2009; 1792 (6): 497-505.
44. Tili E, Michaille JJ, Cimino A, et al,. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol 2007; 179 (8): 5082-5089.
45. Zhang Y, Wei W, Cheng N, et al,. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56 (5): 1631-1640.
46. Ge D, Fellay J, Thompson AJ, et al,. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461 (7262): 399-401.
47. Prokunina-Olsson L, Muchmore B, Tang W, et al,. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45 (2): 164-171.
48. Su C, Hou Z, Zhang C, Tian Z, Zhang J,. Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 2011; 8: 354.
49. Wang P, Hou J, Lin L, et al,. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. J Immunol 2010; 185 (10): 6226-6233.